High blood pressure is an important risk factor for heart disease and is treated by various anti hypertensive medications. Angiotensin receptor blockers (ARB) are established and proven medication for patients with high blood pressure and also, prevent deaths due to heart disease. ARBs are medications which blocks the effect of Angiotensin II and thus leading to dilation of blood vessels which results in reduction in blood pressure. However, a recent research has found that patients on this medication are somewhat more prone to be diagnosed with the cancer than those not consuming it.

Blood pressure lowering drugs may cause cancer. This finding was based on a systemic review and meta analysis of various clinical trials. Such review provides a significant mean to find the overall effect of various treatments. This report included the results of trials done on currently available ARBs and was more specifically focused on effects of ARBs on new cancer development and deaths from cancer. Various scientific databases were searched and clinical trials which included at least 100 patients were considered for analysis. Special care was taken in selection of trials as cancer is a rare adverse event which takes longer time to develop and hence only studies with one year of follow up were included.

Total 5 clinical trials were included in the analysis, which included total of 61,590 participants. The researchers assessed the risk of cancer associated with ARBs medication. The results of meta analysis showed that there was an increased risk of cancer in patients taking ARBs compared with people not taking ARBs. It was seen that risk of new cancer development was 8% higher in patients taking ARBs compared to non ARB users. Additionally, no difference was observed between the ARB and non ARB groups in risk of cancer related deaths.

In conclusion, the report said that ARBs are linked with a slightly increased risk of new cancer diagnosis. This study does not prove that ARBs cause cancer, but the data from this systematic review is suggestive of a link with increased risk that requires further investigation in this area.

There is no reason to panic in case you are taking any medication that are said to be causing cancer. You should try to visit your doctor and ask for a possible alternative that you could take. Also the risk is only slightly more than in people who do not take the ARBs. There could be other factors which could be responsible for the causation of cancer apart from the drugs themselves.

About the Author:
Dr. Anita Brown is a New York based physician. She actively supports Http://www.HealthEnclave.com by writing articles on wide range of topics and interests. She has a passion for writing this coupled with her education credentials as a doctor make her an excellent medical writer.

Abstract
Map the world of the new MSL
As Medical Science Liaisons’ strategic role becomes increasingly multifaceted, measuring and communicating MSLs’ value has never been more important. This study is an all-in-one benchmarking tool: in unprecedented detail, eight chapters spell out MSL activities, program structure and territory sizing, staffing, budgets, performance metrics, and more. Developed from data from 50 Life Sciences companies, the report will enable you to prioritize MSL objectives and bolster team performance.

Embrace the New MSL – and Maximize Impact
MSLs have recently emerged as organizational “go-to” personnel, providing support to internal clients, including sales, clinical and commercial. But both internal groups and MSLs themselves are unclear about the expanded role, diluting MSL effectiveness. Empower the “liaison” part of their role and implement effective strategies for improving coordination with internal groups. Also, breakdowns detailing MSL activities in the office and in the field will aid in better directing MSL efforts and will advance productivity.

Build a Stable of Thought Leader Relationships
While the new MSL model encourages building internal relationships, interacting with thought leaders remains a tremendous ongoing challenge. Develop a clear-cut relationship-building strategy. Metrics reveal which physicians MSLs should target as key opinion leaders. Taking the process a step further, best practices show how to gauge and build close relationships. Most importantly, though, they also show how to develop those relationships into tangible opportunities for the company.

Master MSL Group Management
Superior management facilitates success. Study new structure models and trends designed to elevate team efficiency. Improve territory breakouts: who covers what? How do we divide territories? The report also examines MSL compensation, education, and experience – see how other companies balance these components to refine their recruiting efforts – and shape career paths. Finally, to be fully effective, high-caliber staff need sufficient funding. Use this study’ s budget data to fine-tune resource allocation.

Evaluate and Communicate MSL Performance
Victories alone are not enough to prove MSL value. Program leaders must continually assess team and individual efforts to drive improvement. The study’ s findings show which performance metrics companies are using to assess MSLs’ internal and external value. Use them to design a comprehensive performance measurement tool that incorporates both hard and soft metrics.

Achievements must also be articulated to key stakeholders. This is crucial because part of MSLs’ skills is qualitative. Some groups may not see how MSLs directly influence the bottom line. Our study explores leading companies’ strategies for translating qualitative benefits into quantitative results.

Table of Contents :

Executive Summary
Study Methodology
Study Definitions
Profiled Companies
Six Key Findings and Recommendations
MSL Activity Breakdowns
Pre-Launch Activities
Post-Launch Activities Breakdowns
Time Spent per Activity for MSLs in Other Major Markets
Thought Leader Identification and Development
Building and Maintaining Relationships with Thought Leaders
Internal Value-Adding Activities
Supporting the Sales Team
Growing Internal Responsibilities
Applying Performance Metrics to MSL Teams
Overall Use of Performance Metrics
Percentage of Companies That Perform Each MSL Metric by Company Type
External Value Metric Use by Number of Metrics and Company Type
Internal Value Metric Use by Number of Metrics and Company Type
MSL Performance Measurement by Companies in Other Major Markets

For more information please contact :

http://www.aarkstore.com/reports/Internal-Thought-Leader-External-Voice-and-Clinical-Catalyst-42758.html

http://blogs.aarkstore.com/

From:Aarkstore Enterprise
Contact: Neel
Email: press@aarkstore.com
URL: www.aarkstore.com

About the Author:
Aarkstore Enterprise specialize in providing online market business information on market research reports, books, magazines, conference booking at competitive prices, and strive to provide excellent and innovative service to our customers.

Since ages, we have been talking about the role of ethics in each and every sphere of our life. As the subject of ethics deals with values, beliefs and opinions; it is a creation of the human mind in accordance with time, place and situation. When ethics is all about building and maintaining a strong moral character, how can clinical research be justified?

Clinical Research Education involves the use of a particular person or a group of persons as the subject for the medical trial in order to develop new drugs, dosage regimens, surgical and diagnostic techniques and therapies. But, in the light of ethics, the use of human beings as subjects can not be accepted, as every life is equally precious and it is highly unethical to put a few lives on stake for the welfare of the rest. There has to be a middle path- where clinical research can be strived for idealism without stopping the human experimentation. There is a need for the society to facilitate the clinical research and protect the practice of ethics, ensuring the fortification of people from any abuse or harm at the same time.

Ethical practices have a multiplicity of roles in the conduct of clinical research. Clear understanding of the ethical principles particularly in respect of the recruitment of subjects and in addressing the major ethical issues of the clinical trials is the need of the hour. Some of the most common and the most general principles of clinical ethics are: respect, autonomy, beneficence and justice towards persons. As clinical research involves human participants, researchers and their teams are legally and ethically obliged to protect them. The subjects should be treated as autonomous individuals whose welfare and rights should be respected. The investigators must thrive to minimize the harm and enhance the benefits to the study population.

Ethical process in the clinical research is quite formalized and centralized. Various international ethical codes and guidelines have been issued in the context of clinical research. These include:

Nuremberg Code

World Medical Association Declaration of Helsinki.

The Belmont Report

The American Nurses Association Code etc.

No clinical trials involving human subjects should be conducted without strict adherence to the principles given in these codes. This signifies the importance of the knowledge of ethics for the students of clinical research. Courses in clinical research must develop a strong moral and ethical base in order to make the students aware of their social responsibility. ICRI UK provides a masters degree in clinical research along with spreading the knowledge of ethics.

In a nutshell, it can be concluded that contemporary ethical issues in the arena of clinical research are no less than the issues of global justice.

About the Author:
ICRI UK is recognized medical university in UK offering a wide range of courses to suit your needs and provides with unequalled opportunities. They offer Clinical Research Education and Courses in clinical research.

Green tea, just like the acai berry and pomegranate, has been touted as perhaps the best weight loss product you can consume, but is it really a cure-all for weight gain? Is it any better than other drinks for controlling your weight loss?

Green tea comes from the same tea leaves–Camellia sinensis–as black tea and other kinds of teas. The difference is that green tea receives minimal oxidation during processing. It is rich in antioxidants such as polyphenols, especially catechins, as well as carotenoids, tocopherols, ascorbic acid (Vitamin C), and other minerals.

This abundance of good-for-you compounds makes green tea a great drink for the health-minded individual. But does it live up to the weight loss claims?

Possible Benefits of Drinking Green Tea

Because of the rich mixture of healthy compounds green tea contains, it has become the darling of the diet set, a beverage that supposedly gives amazing health benefits and aids in weight loss.

Green tea has been reported to aid in the treatment or prevention of Alzheimers disease, Parkinsons disease, cancer, and multiple sclerosis. It has also been touted as a way to combat free radicals in the body, and as a way to lower LDL (bad) cholesterol levels and elevate levels of HDL (good) cholesterol in the bloodstream.

Some researchers also claim that drinking green tea can increase metabolic rates and burn extra calories. Because green tea contains less caffeine than coffee, it has also been used to wean people off of a coffee or soda-induced caffeine addiction. With all of these claims, its difficult to separate fact from fiction.

What Scientists Say

Of all the claims that have been made about the health benefits of drinking green tea, the Food and Drug Administration will only agree to one claim. The agencys official response is that there is very limited credible evidence for qualified health claims specifically for green tea and breast cancer and for green tea and prostate cancer, provided that the qualified claims are appropriately worded so as to not mislead consumers.”

A number of independent studies have proven some limited claims about the health benefits of consuming green tea. (For more information on the numerous scientific studies conducted on green tea, read through the American Journal of Clinical Nutrition and other medical abstracts.)

As for weight loss, the American Journal of Clinical Nutrition published a study in its January, 2005 edition concluding that drinking green tea every day for 12 weeks reduced overall body fat. However, these claims have not been verified by the FDA.

The Bottom Line

Green tea does offer a potential host of benefits to tea drinkers, but is it really the best weight loss product? As you can probably imagine, there is no magic cure for weight loss, so green tea should not be used as a cure-all for obesity.

Because of its rich levels of minerals, vitamins, and antioxidants, however, it should be incorporated into a healthy diet program. Replacing sodas and juices with more health-giving beverages such as green tea is a great step forward on the road to getting fit and staying fit.

About the Author:
Are you looking for an HONEST and ALL-NATURAL Diet & Nutrition Program? Visit Beyond Diet up for a free video filled with Tips and Tricks to Jumpstart Your Weight Loss. Stop DietingStart Eatingand Start Living! http://www.beyonddiet.com/

Healthmed Services, Ltd. (OTC:HEME), is developing a remote software product that will mobilize healthcare professionals and increase their efficiency by allowing them to interact with their stationary PC and do electronic charting from anywhere in the facility and also also them to update patient records, all via an iPAd. The product is an innovative measure that will simplify record-keeping.

HEME, an innovative software development company, is pleased with the recent studies and reports on information technology spending. HEME foresees their products as being a nice fit in the technology upgrades being made as part of the healthcare industry modernization. It is expected that healthcare spending in general could reach 4.5 trillion dollars by 2019.

President Obama has pledged 630 billion dollars over the next 10 years to the industry.

The US American Recovery and Reinvestment Act of 2009 has already awarded 70 billion dollars through the US Department of Health and Human Services to the healthcare industry. According to Juniper Research, spending on mobile hardware, software and services across the global healthcare sector is set to rise to $2.7 billion in 2010.

According to Forresters research for the first quarter, U.S. spending on information and communications technology products and services will reach 741 billion dollars in 2010.

HEME is optimistic their objective is in concert with the plans and goals of the healthcare industry. HEME will continue to build products and services that help professionals work more efficiently, help organizations provide convenience to their staff, and add value to the technical side of healthcare.

HealthMed also plans to provide online services through its Web site that includes a public portal, a Web site for individuals, consumers, and the general public that is designed to provide health information and recommendations; and a private and custom-designed/client-specific portal, a private-labeled Web site that would allow employees to access their personal health records and research various health and medical related topics, as well as provide access to information and resources to assist them in making personal health plan and medical treatment decisions.

You may read more about HEME and its product developments on its website: www.healthmedltd.com

Regeneron Pharmaceuticals, Inc. (Nasdaq:REGN) will webcast its presentation at the Morgan Stanley Global Healthcare Conference on Monday, September 13, 2010. The presentation is scheduled for 1:00 p.m. Eastern Time.

The session may be accessed through REGN’s web site, www.regeneron.com, on the Investor Relations page. An archived version of the presentation will be available after the live webcast through October 13, 2010.

Regeneron is a fully integrated biopharmaceutical company that discovers, develops, and commercializes medicines for the treatment of serious medical conditions. In addition to ARCALYST (rilonacept) Injection for Subcutaneous Use, its first commercialized product, Regeneron has therapeutic candidates in Phase 3 clinical trials for the potential treatment of gout, diseases of the eye (wet age-related macular degeneration and central retinal vein occlusion), and certain cancers.

Additional therapeutic candidates developed from proprietary Regeneron technologies for creating fully human monoclonal antibodies are in earlier stage development programs in rheumatoid arthritis and other inflammatory conditions, pain, cholesterol reduction, allergic and immune conditions and cancer.

StemCells, Inc. (Nasdaq:STEM) announced recently that its technology was recently used by independent researchers to achieve the first genetically engineered rat derived from rat embryonic stem (ES) cells. This breakthrough, published this month in the international peer-reviewed journal Nature, opens the door to the types of genetic manipulations previously only possible in mice, and paves the way for modeling a broader range of human diseases with the rat. Both mice and rats are used as animal models of human disease; however certain aspects of the rats physiology, behavior, and metabolism are closer to the human, making rats the preferred species for drug development and studying human disease. The creation of this first rat model using rat ES cells validates intellectual property owned by StemCells, which includes the rights to patents covering both rat ES and rat induced pluripotent stem (iPS) cells as well as genetically engineered rats derived from these cells.

STEM’s broad rat pluripotent stem cell intellectual property portfolio is based upon groundbreaking research led by prominent academic researchers at the University of Edinburgh, including Dr. Qi-Long Ying who was the first to succeed in deriving and culturing the true germline competent rat ES cells required for precise genetic engineering. In this newly published study, Dr. Qi-Long Ying and his colleagues at the Eli and Edythe Broad Center for Regenerative Medicine and Stem Cell Research at the University of Southern California demonstrated for the first time the creation of genetically modified rats using rat ES cells that have been gene targeted via homologous recombination, a method which involves adding DNA sequences to the cells to delete (‘knock-out’), add (‘knock-in’) or otherwise modify genes of interest. This latest work resulted in the successful generation of knock-out rats missing the tumor suppressor gene p53 for use in studying cancer1, and serves as a proof-of-principle for creating genetically engineered rats using rat ES cells.

StemCells, Inc. is engaged in the research, development, and commercialization of stem cell therapeutics and tools for use in stem cell-based research and drug discovery. In its therapeutic product development programs, StemCells is targeting diseases of the central nervous system and liver. StemCells lead product candidate, HuCNS-SC(R) cells (purified human neural stem cells), is in clinical development for the treatment of two fatal neurodegenerative disorders that primarily affect young children. StemCells also markets specialty cell culture products under the SC Proven(R)brand, and is developing stem cell-based assay platforms for use in pharmaceutical research, drug discovery and drug development. The Company has exclusive rights to approximately 55 issued or allowed U.S. patents and over 200 granted or allowed non-U.S. patents.

For FREE Daily Stock Alerts & Updates Signup At: http://pennytobuck.com/signup

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. PennyToBuck.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers.Our disclaimer ( http://pennytobuck.com/disclaimer) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold PennyToBuck.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. Rule 17B requires disclosure of payment for investor relations.The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period. Crown Equity Holdings Inc. (CRWE.OB) has received five thousand dollars in cash from a third party (Media Elite Consultants LLC) for (1) day of advertising for Healthmed Services Ltd. (OTC BB: HEME.OB)

About the Author:

Answers to 5 Frequently Asked Questions About Chiropractors And Chiropractic Care

1. What do chiropractors do?
Doctors of Chiropractic are health care professionals who specialize in conditions of the spine and and nervous system conditions and how they affect a persons overall health. Chiropractors focus on eliminating pain in the back, neck, and joints as well as headaches. Chiropractors seek to correct conditions that cause these pains.

2. What kind of training do chiropractors receive?
The rigorous educational requirements for chiropractors are similar to the requirements for your family doctor. Both certifications require a 4 year program of study and almost 5000 hours of classroom and clinical study hours. For MDs and Chiropractors, the first 2 years of study are very similar. In years 3 and 4, for the chiropractor, greater emphasis is placed on biomechanics, radiology, adjustments and natural medicine.

3. How are chiropractors licensed?
Like most other health care practitioners, chiropractors are licensed at the state level by a state board of chiropractic examiners. Chiropractors also required to complete many hours of continuing education each year to keep their licenses current.

4. What are the advantages of seeing a chiropractor?
Unlike surgical procedures, chiropractic care is non-invasive. Drugs, such as addictive painkillers, are not part of the practice. Normally, the cost of treatment is far lower. People who tried other medical options without resolving the problem often find chiropractic care provides relief.

5. Is chiropractic safe?
Although no form of medical treatment is totally without risk, this non-invasive, drug-free approach to whole body care has earned respect. That is why chiropractors enjoy an exceptional safety record.

How to choose a chiropractor:

When selecting a chiropractor, take time to find a licensed Chiropractic Doctor who has experience treating your specific condition, uses diagnostic tools such as x-rays and ultrasound, will work with your other physicians as part of your medical team, and will provide an initial consultation without charge.

If you have spine-related pain, this FREE Guide will help you get relief right away. And if pain relief from a Doctor of Chiropractic is what you need most, this Guide will help you make the best possible choice for your personal pain relief needs.

To get the FREE Pain Relief Guide, simply visit Best Chiropractor Westminster CO. See you there!

About the Author:
We are a Chiropractic Care Center in Westminster Colorado who is dedicated to creating healthier, pain free lives.

Visit us at http://wwww.BestChiropractorWestminsterCO.com to receive your FREE pain relief guide–the natural way. And if you decide that receiving care from a Doctor of Chiropractic is what you need most, find out how to choose the best chiropractor for your personal needs.

Copyright 2010 Key Market Research, llc

Medicine is a noble profession but a damn bad business. This is a very famous quote by Rolleston, Humphrey which points out at the unethical conducts and malpractices taking place under the cover of the great noble profession of Medicine.

In the realm of medical science, clinical trials have become a key instrument in the discovery and invention of new medicines or medical procedures for the betterment of humanity. Clinical research, which is an eminent branch of medical science, determines the safety and effectiveness of medications, medical equipments, diagnostic product and various treatment procedures intended for the use of humans. The continuous growth of the pharmaceutical industry has led to the rising demand for clinical research studies; but at the same time, it has contributed to the rise in the number of clinical trial frauds.

Misconduct and fraud are serious offences and can have major impact on the trials, leading to serious and grave consequences as they may put on stake various human lives. It is in the light of regulating such demeaning practices that various regulatory codes and guidelines have been set up for recording, monitoring and analyzing the proceedings and the outcomes of the clinical trial studies. The most important set of such regulatory guidelines is that of GCP- i.e. Good Clinical Practice.

GCP is an internationally qualified standard that has been drafted by the ICH (International Conference on Harmonization) for governing the clinical trials with a set of guidelines that must be followed strictly. These guidelines aim at the protection of human rights in the practice of various clinical trials. They also assure the safety and efficacy of the newly developed medications and treatments. The GCP guidelines set up a framework defining the conduct of procedures, roles and responsibilities of clinical researchers, investigators and the monitors.

GCP is a universally applicable set of 13 core principles which adhere to all clinical investigations affecting the safety and well-being of the human participants. An in-depth study and understanding of these principles is a must for all those associated with the field of clinical research. Even for the students, who are planning to make their careers in this noble profession, a specialized training or course of study of these principles is essential.

There are various clinical research courses that provide a thorough knowledge of the GCP requirements for the clinical requirements. They help the students in gaining experience in detecting, correcting and preventing clinical study deficiencies during the course of action.

Courses in Clinical Research also teach them accurate, factual and appropriate documentation procedures so as to avoid all possible un-intentional errors. ICRI Singapore is one such renowned institute which offers a Masters in Clinical Research. It aims at providing the medical, pharmacy and life-science graduates with an advanced understanding of the methodologies and processes required in the practical clinical healthcare applications.

Aim at maintaining the nobility of the unique and dignified profession of Clinical Research by adhering to the guidelines mentioned in the GCP.

About the Author:
ICRI Singapore is recognized health care medical university offering a wide range of courses to suit your needs and provides with unequalled opportunities. They offer Clinical research education and Courses in Clinical research courses.

I am often asked by pregnant women if the artificial sugar Aspartame is safe for them and their developing babies. Postnatal mothers also ask me if it is safe for them to drink aspartame sweetened diet drinks for postpartum weight loss.

My answer to both questions is an emphatic No!

Heres why:

Aspartame is sold as NutraSweet, Equal, Spoonful, and Equal-Measure. These artificial sweeteners are all aspartame, just with different names. Neuroscientist, Dr. Russell Blaylock discusses in his book Excitotoxins that there are several toxic breakdown chemicals from these aspartame products that make them dangerous for a developing fetus but also for mothers.
The major concerns about pregnant women ingesting aspartame during pregnancy are birth defects and damage to certain areas of the brain. This potential brain damage includes the parts of the brain involved in complex learning and hormone control.

Aspartame Disease

Since the FDA gave this Aspartame its blessing in 1981, aspartame has accounted for more than 75 percent of all complaints reported to the FDAs Adverse Reaction Monitoring System!
Aspartame disease refers to a constellation of symptoms attributed to the use of products containing aspartame. Out of the over 90 documented symptoms, the most common occurrences include:

Headaches/Migraines
Dizziness
Mental Confusion
Slurred Speech
Ringing in the ears
Nausea
Numbness

The Three Chemical Components of Aspartame

Aspartame has three chemical components:

(1) Phenylalanine (50 percent)
(2) Aspartic acid (40 percent)
(3) Methanol, also called wood alcohol, (10 percent).

Those in support of this very popular artificial sweetener (including the FDA and its patent owner Monsanto who has aspartame yearly sales over $1 billion), state that the two primary amino acids, which comprise 90 percent of aspartame by weight, are a harmless and natural part of our diet.

They insist phenylalanine is a harmless amino acid precursor to the neurotransmitters adrenaline, nor-adrenaline, and dopamine and that aspartic acid is a naturally occurring neurotransmitter, which is already present in the human central nervous system. This is only a partial truth.

Phenylalanine and aspartic acid are amino acids that are normally supplied by the foods we eat; however, they can only be considered natural and harmless when consumed in combination with the other amino acids in foods. On their own, they enter the central nervous system in abnormally high concentrations, causing excessive firing of nerve cells and potential nerve cell death. The toxic effects of these amino acids, when consumed in excessive isolated amounts, can be linked to a very long list of serious side effects and symptoms.

Very worrisome is the 10 percent of aspartame that is absorbed into the bloodstream as methanol (wood alcohol). The Environmental Protection Agency (EPA) defines safe consumption as no more than 7.8 milligrams per day of this dangerous substance. A one-liter beverage, sweetened with aspartame, contains about 56 milligrams of wood alcohol, or eight times the EPA limit!

Even Scarier Breakdown Chemicals

Aspartames breakdown products are even scarier than its components. Phenylalanine decomposes into diketopiperazine (DKP) a known carcinogen, when exposed to warm temperatures or prolonged storage.

To make matters even worse, at cold temperatures, methanol will spontaneously give rise to a colorless toxin known as formaldehyde. Independent studies have shown formaldehyde formation resulting from aspartame ingestion to be extremely common. It accumulates within the cells, and reacts with cellular proteins such as enzymes and DNA. This cumulative reaction could spell grave consequences for those who consume aspartame-laden diet drinks and foods on a daily basis.

DKP has been implicated in the occurrence of brain tumors. It is proven that DKP is formed in liquid aspartame containing products during prolonged storage.

Dangers for Fetuses and Newborns

Before birth and during the first 12 months of infant life, the blood-brain barrier (a barrier that prevents unwanted chemicals from entering the deepest recesses of the brain) is not yet completely formed. Because a fetus and infants blood brain barrier is not yet formed, dangerous excitotoxins, such as the aspartic acid and phenylalanine contained in aspartame, are given free access to the child’s nervous system. Additionally, the concentrating effects of the placenta are able to magnify the levels of phenylalanine in the blood by as much as 400%-600% in a fetus!

Fetal phenylalanine has the potential to reach levels that kill cells in tissue culture. It has been determined that infants are four times more sensitive to excitotoxins than adults. During the first year of life, irreversible brain damage can occur through agents contained in breast milk.
Despite this, the American Dietetic Association still recommends aspartame for pregnant and nursing women!

Brain Damage and Seizures

Brain damage from aspartame ingestion is believed to occur through flooding the brain with large amounts of phenylalanine, disturbing the balance of neurotransmitters, and methanol-induced brain swelling. Aspartic acid is a neuro-excitatory toxin present in damaging amounts even at the accepted daily intake for aspartame.

Formaldehyde, which is derived from methanol, accumulates in certain areas of the brain that correspond to the neurodegenerative symptoms of Parkinson’s, Alzheimer’s and ALS (Lou Gehrig’s Disease). These conditions are all associated with free radical injury, a proven effect of the excitotoxins phenylalanine and aspartic acid. Recent studies have established that aspartame has seizure-promoting activity in animals. It is believed that aspartame can increase seizure frequency among epileptics and even initiate seizures in susceptible individuals with no prior history of seizures.

Depression and Anxiety

Excitatory neurotransmitters use up excessive amounts of the relaxing, antidepressant neurotransmitters serotonin and GABA. This can lead to postpartum depression, postpartum anxiety disorder, and insomnia.

Aspartame Research Ignored

For over eight years, the FDA refused to approve aspartame because it was known to produce seizures and brain tumors in laboratory animals.
Searle Pharmaceuticals was the original developer of Aspartame. One pivotal study by Searle’s researchers, known as the “Waisman Study,” initially indicated that ingestion of Aspartame caused convulsions and death in monkeys. However, official conclusions could not be reached because the study was never completed. Searle blamed limitations in adequately skilled laboratory personnel for their decision to terminate the study. By Searle’s own acknowledgement, his team lacked competent research staff. Two FDA investigative task forces presented scathing reports on the quality of the company’s research and in 1976, the FDA’s general counsel requested a federal grand jury investigation of the company. For reasons unknown, the investigation was never undertaken.

Initially, even the National Soft Drink Association (NSDA) rallied against the use of Aspartame. An excerpt of a protest submitted for congressional review in 1983 reads:

“Of approximately 100 independent studies conducted on aspartame, over 90 percent have demonstrated significant health risks. Why hasn’t aspartame been banned? In 1996, ignoring the fact that aspartame breaks down faster when heated above 86 degrees Fahrenheit, the FDA decided to remove any remaining limitations on its use. Presently, there are thousands of companies using aspartame in diet sodas, powdered drinks, gelatin, tea, coffee, cocoa, juices, frozen desserts and even medications. This translates to billions of dollars of profits worldwide. Unfortunately, this is more than enough to provide agency officials with lucrative future employment, politicians with campaign funds, non-profit foundations with endowments, scientists with research grants and the media with millions in advertising dollars.”
Even now, FDA officials continue to resist the many proposals from concerned scientists, physicians and other groups for comprehensive studies regarding the safety of aspartame.

My Final Recommendation

This is why I recommend all pregnant and postpartum women avoid all food and drink that contains Aspartame (NutraSweet, Equal, Spoonful, and Equal-Measure).

In fact, I recommend that all people avoid this unsafe chemical. The dangers of the artificial sweetener aspartame are far from sweet!

Dr. Dean Raffelock is the lead author of A NATURAL GUIDE TO PREGNANCY AND POSTPARTUM HEALTH published by Avery in 2003. He is a holistic doctor who has been in private since 1977 and practices in Boulder, Colorado. He has earned four board certifications including clinical nutrition, acupuncture, chiropractic, and applied kinesiology and continues to teach research-based clinical nutrition for numerous medical organizations. Dr. Raffelock is Vice President of Research and Development for Soundformulas.com the makers of After Baby Boost- the first and only clinically tested comprehensive postnatal nutrient system and Before Baby Boost the first and only comprehensive 3 bottle prenatal nutrient system. He is also President of Sound Formulations, LLC a consulting company that formulates and manufactures premium quality nutritional products for nutriceutical companies. He may be reached at DrDeanR@Soundformulas.com, http://SoundFormulas.com

About the Author:
Dean Raffelock D.C., L. Ac., CCN, DIBAK

3100 Arapahoe Ave. #202

Boulder, CO 80303

303-431-9019

President- Sound Formulations, LLC

Vice President- Sound Formulas, LLC

Dr. Dean.Raffelock@gmail.com

DrDeanR@Soundformulas.com

Nursing programs are courses that have to be taken in order to generate entrants into the ever-growing nursing profession. Through a progression of steps and programs designed to develop and enhance nursing skills, nurses are kept abreast of new technologies and improvements in healthcare administration and patient care.

Licensed Registered Nurses (RNs) are required to complete a four-year or baccalaureate nursing program in community colleges and campus-based settings. A Bachelor of Science in Nursing (BSN) degree is needed by entry-level nurses to get hospital jobs.

Graduate programs for nurses include master’s degree programs and doctoral studies. These are offered mainly by large universities. Nurses in pursuit of advanced practice or specialized nursing degrees enroll in programs for nurse anesthetists, nurse midwives, nurse practitioners, and clinical nurse specialists. Doctoral degrees, on the other hand, lean towards research, nursing practice, and the science of nursing itself. Graduate nursing programs give students the chance to work alongside physicians and highly experienced nurse educators. These also offer the opportunity of working in cutting-edge technology settings and using the most modern medical facilities.

There are two- to three-year non-degree programs that are hospital-based and offer certification for graduates. Often, they become employed by the host hospital upon completion of the course.

Online nursing programs make it easier for nurses to stay successful and competitive within the profession. There are a variety of online nursing degrees that are available, on all the levels that have been mentioned above: bachelor’s, master’s, doctoral, certificate’s, and associate’s degrees. Popular online programs include an MBA in Healthcare Administration, nurse practitioner programs, geriatric nursing, and so on.

Online study is increasingly becoming the mode of choice in getting a nursing degree. While there are schools that offer both traditional degrees and online degrees on selected specialty programs, there are nursing schools that are entirely online, thereby offering an entirely different nursing school experience. At best, it is a more convenient way of completing a nursing education, and there is assurance that nursing education received online is of the same high quality as a nursing education gained from a traditional school.

It is very important for an online nursing school to be properly accredited. National accreditation of nursing schools is done through the Commission on Collegiate Nursing Education (CCNE) and the National League for Nursing Accreditation Commission (NLNAC or NLN). There are also standardized testing and licensure requirements across the USA that have been designed to ensure that the quality of nursing education you get online isont par with traditional, campus-based nursing programs.

There are several factors to consider in choosing a nursing program. Cost is a major consideration. Traditional, institution-based programs are more costly than online programs. They are also more rigid in terms of schedules and course duration. Whatever your choice, what counts most is diligence and discipline in achieving the goal you set out for in signing up with the nursing program.

About the Author:
Need to know the nursing profession? Discover the requirements and learn about online nursing programs from http://www.careertoolkits.com

Clinical Trials: World Market 2010-2025

The market for clinical trial services has been expanding rapidly, with impressive revenue growth and expansion of the sector in recent years. Our new study shows how that sector will develop from 2010 onwards, with benefits to the pharma industry and clinical service providers. Clinical research organisations (CROs) are playing increasingly important roles in drug development worldwide, from conducting phase I trials to post-marketing studies. ( http://www.bharatbook.com/detail.asp?id=149094&rt=Clinical-Trials-World-Market-2010-2025.html )

Ageing populations, increasing prevalence of chronic diseases, growing demand for improved therapies and high growth of the pharmaceutical and biotechnology markets worldwide are driving the clinical trials sector and market. The globalisation of development programmes and the increasing complexity of trials with regulatory developments are heightening the need for larger trials and greater numbers of trials. Many pharma companies are outsourcing clinical trials to gain cost savings/efficiencies, greater flexibility and specialist expertise. That trend will continue from 2010 onwards, our new study Clinical Trials: World Market 2010-2025 reveals. The emerging clinical trial destinations, including CEE countries, India and China, are achieving double-digit growth, our analyses show.

Our new report considers perspectives of sponsors and CROs for clinical trial outsourcing/off-shoring. We analyse the sectors strengths, weaknesses and financial prospects from 2010 to 2025 through quantitative and qualitative analyses. This report provides hard-to-find data on the current and future values of clinical trial spending and the CRO market, worldwide and regionally. We address global questions, such as: what proportion of the sector will be held by contract research organisations in future years? Our report also addresses regional questions. For example, how will Indias share of global spending change between 2010 and 2025? Will the Central and Eastern European sector expand more rapidly than that of China? Our new report answers questions such as those, providing the information that you need.

Detailed analysis of the global clinical trials market

Clinical Trials: World Market 2010-2025 examines that sector critically, through a comprehensive review of information sources. We harness primary and secondary research. This report provides detailed sales forecasts, market share analyses and analyses of commercial drivers and restraints, including SWOT analysis. There are over 50 tables and figures and two full interviews with experts on the sector. The result is a comprehensive market- and industry-centred report, with detailed analyses and informed opinion to benefit your work.

For more information kindly visit : http://www.bharatbook.com/detail.asp?id=149094&rt=Clinical-Trials-World-Market-2010-2025.html

Related Reports

Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
http://www.bharatbook.com/detail.asp?id=132644&rt=Clinical-Trial-Recruitment-Strategies-Optimizing-patient-recruitment-and-retention-in-late-stage-clinical-trials.html

Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
http://www.bharatbook.com/detail.asp?id=144409&rt=Investigating-Clinical-Trial-Costs-Comparative-analysis-of-trial-cost-components-in-key-geographies.html

Or

Contact us at :

Bharat Book Bureau
Tel: +91 22 27578668
Fax: +91 22 27579131
Email: info@bharatbook.com
Website: www.bharatbook.com
Follow us on twitter: http://twitter.com/3bbharatbook
Please visit our blog at http://bharatbookseo.blogsome.com

About the Author:
Bharat Book Bureau facilitates companies to take the lead of their industry with best practice business strategies and intelligence, through a unique combination of published reports, databases, country reports, company profiles and customized research services. Bharat Book Bureau provides strategic information tools to the executives, business analysts, and knowledge managers that will help them to probe into and support critical, timely business decisions and strategies.